Clotting Propensity of Surface-Treated Membranes in a Hemodialysis Set-up That Avoids Systemic Anticoagulation

Semin Nephrol. 2023 Nov;43(6):151482. doi: 10.1016/j.semnephrol.2023.151482. Epub 2024 Jan 23.

Abstract

The development of biocompatible membranes, aiming to limit the inflammatory response, oxidative stress, and coagulability during hemodialysis, has been an important step in reducing dialysis-related adverse outcomes. This includes a reduction in the risk of clotting of the extracorporeal circuit, thus enabling hemodialysis with a reduced dose or even without systemic anticoagulant drugs in patients with an increased bleeding risk. In this article, we summarize the in vitro research and clinical evidence on the antithrombotic properties of vitamin E- and heparin-coated membranes.

Keywords: Anticoagulation; dialyzer; hemodialysis; heparin-coated; membrane; vitamin E-coated.

Publication types

  • Review

MeSH terms

  • Anticoagulants* / therapeutic use
  • Blood Coagulation* / drug effects
  • Coated Materials, Biocompatible
  • Heparin* / therapeutic use
  • Humans
  • Membranes, Artificial*
  • Renal Dialysis* / methods
  • Vitamin E* / therapeutic use

Substances

  • Membranes, Artificial
  • Heparin
  • Anticoagulants
  • Vitamin E
  • Coated Materials, Biocompatible